Folgen
Roman Sukhovershin
Roman Sukhovershin
Scientific Director - RNA therapeutics, Houston Methodist Research Institute
Bestätigte E-Mail-Adresse bei houstonmethodist.org - Startseite
Titel
Zitiert von
Zitiert von
Jahr
The limitless future of RNA therapeutics
TR Damase, R Sukhovershin, C Boada, F Taraballi, RI Pettigrew, ...
Frontiers in bioengineering and biotechnology 9, 628137, 2021
3752021
Proton pump inhibitors accelerate endothelial senescence
G Yepuri, R Sukhovershin, TZ Nazari-Shafti, M Petrascheck, YT Ghebre, ...
Circulation research 118 (12), e36-e42, 2016
1452016
Rapamycin-loaded biomimetic nanoparticles reverse vascular inflammation
C Boada, A Zinger, C Tsao, P Zhao, JO Martinez, K Hartman, T Naoi, ...
Circulation Research 126 (1), 25-37, 2020
1232020
Biomimetic nanoparticles with enhanced affinity towards activated endothelium as versatile tools for theranostic drug delivery
JO Martinez, R Molinaro, KA Hartman, C Boada, R Sukhovershin, ...
Theranostics 8 (4), 1131, 2018
962018
Endothelium-derived nitric oxide as an antiatherogenic mechanism: implications for therapy
RA Sukhovershin, G Yepuri, YT Ghebremariam
Methodist DeBakey cardiovascular journal 11 (3), 166, 2015
602015
How may proton pump inhibitors impair cardiovascular health?
RA Sukhovershin, JP Cooke
American Journal of Cardiovascular Drugs 16, 153-161, 2016
502016
mRNA-enhanced cell therapy and cardiovascular regeneration
PK Chanda, R Sukhovershin, JP Cooke
Cells 10 (1), 187, 2021
212021
Local inhibition of macrophage and smooth muscle cell proliferation to suppress plaque progression
RA Sukhovershin, NET Furman, E Tasciotti, BH Trachtenberg
Methodist DeBakey cardiovascular journal 12 (3), 141, 2016
202016
Метиларгинины у крыс в глицериновой модели острой почечной недостаточности
МА Гилинский, РИ Айзман, ГА Корощенко, ТВ Латышева, ...
Сибирский научный медицинский журнал 30 (4), 82-86, 2010
192010
RNA therapeutics for cardiovascular disease
C Boada, R Sukhovershin, R Pettigrew, JP Cooke
Current opinion in cardiology 36 (3), 256-263, 2021
172021
The limitless future of RNA therapeutics. Front. Bioeng. Biotechnol. 9, 628137
TR Damase, R Sukhovershin, C Boada, F Taraballi, RI Pettigrew, ...
142021
The influence of acute renal injury on arginine and methylarginines metabolism
RA Sukhovershin, MA Gilinsky
Renal failure 35 (10), 1404-1411, 2013
102013
Regulation of pathological blood-brain barrier for intracranial enhanced drug delivery and anti-glioblastoma therapeutics
K Wang, F Zhang, C Wen, Z Huang, Z Hu, Y Zhang, F Hu, L Wen
Oncology Research 29 (5), 351, 2021
5*2021
Влияние миоглобинурической почечной недостаточности на продукцию оксида азота у крыс
РА Суховершин
Сибирский научный медицинский журнал 32 (3), 34-38, 2012
42012
Methylated arginine analogues: their potential role in atherosclerosis and cognition using the poloxamer-407-induced mouse model of dyslipidemia
MA Gilinsky, TP Johnston, NA Zhukova, NI Dubrovina, TV Latysheva, ...
Canadian Journal of Physiology and Pharmacology 94 (11), 1122-1131, 2016
32016
Endotheliumderived nitric oxide as an antiatherogenic mechanism: implications for therapy. Methodist DeBakey Cardiovasc J 2015; 11 (3): 166-71
RA Sukhovershin, G Yepuri, YT Ghebremariam
32015
The role of asymmetric dimethylarginine in the regulation of nitric oxide level in rats with acute renal injury
RA Sukhovershin, MA Gilinskiĭ
Rossiiskii Fiziologicheskii Zhurnal Imeni IM Sechenova 98 (4), 497-505, 2012
32012
Cerebral hemodynamic reaction to physical exercise of moderate intensity
VP Kulikov, KK Gatal'skiĭ, NL Doronina, K IaA, PA Sukhovershin
Rossiiskii Fiziologicheskii Zhurnal Imeni IM Sechenova 93 (2), 161-168, 2007
32007
Biomimetic nanoparticles with enhanced affinity towards activated endothelium as versatile tools for theranostic drug delivery. Theranostics, 2018, 8 (4), 1131-1145
JO Martinez, R Molinaro, KA Hartman, C Boada, R Sukhovershin, ...
3
Endothelial dysfunction, a major event in atherosclerosis: PPIs impair endothelial function through activation of PAI-1
G Yepuri, R Sukhovershin, TZ Nazari-shafti, YT Ghebremariam, JP Cooke
Atherosclerosis 241 (1), e5, 2015
22015
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20